Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282703 | 1.00 | CA1 (0.46) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL27536452 | 1.00 | CA1 (0.46) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL1287355 | 0.90 | CA1 (0.47) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL7701970 | 0.89 | NPC1 (0.45) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL5142558 | 0.89 | NPC1 (0.45) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL28454216 | 0.88 | CA1 (0.45) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL7701967 | 0.87 | NPC1 (0.46) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL7105161 | 0.87 | MEN1 (0.40) | CA1CA2MMP2CA9ALDH1A1 | |
| SCHEMBL3720801 | 0.87 | ELANE (0.42) | NPC1RAB9AELANEALDH1A1TSHR | |
| SCHEMBL4265208 | 0.86 | NPC1 (0.47) | CA1CA2MMP2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1928475-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-SUBSTITUTED PRONUCLEOTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| WO-2007020193-A2 | ANTIVIRAL PHOSPHORAMIDATES OF 4 ' -SUBSTITUTED PRONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | CA1 4798/4885CA2 4632/4885MMP2 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.